Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF

Healthcare Biotechnology


GREY:IPHAF - Post by User

Isotechnika Pharma Inc > priority review
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by WASKERWISKon Apr 30, 2010 2:18pm
562 Views
Post# 17049794

RE: priority review

RE: priority review

Player, TeeVee is a disingenuous, intellectually dishonest flake.  It is also very weird that he continues to post here.  Creepy weird.

Anyway, FDA obviously doesn’t give priority review to drugs where its probable that the priority will be a waste of time. 

Obviously also, if the median approval time for priority review is 6 months (it varies but it is around there) and if FDA's stated goal for approval is 6 months, it is a statistically unavoidable conclusion that not a whole lot of priority review filings are being delayed.  Not to say it can’t happen of course; just that it is quite improbable

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities